AILERON THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 2nd, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations • Massachusetts
This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Aileron Therapeutics, Inc., a Delaware corporation (the “Company”) and Evan Lippman of Hingham, MA (the “Executive”).
SEVENTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • June 2nd, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations • Delaware
SEVENTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT, dated as of December 23, 2016 (this “Agreement”), among AILERON THERAPEUTICS, INC., a Delaware corporation (the “Issuer”), and the investors in the Issuer named in Schedule I hereto (collectively, the “Investors”), amending and restating the Sixth Amended and Restated Investor Rights Agreement, dated as of October 14, 2014 (the “Sixth Amended and Restated Investor Rights Agreement”), among the Issuer and the Investors.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • June 2nd, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations • Massachusetts
This Amended and Restated License Agreement (this “Agreement”) is entered into as of the 19th day of February, 2010 (the “Effective Date”), for the purpose of amending and replacing the License Agreement dated August 2, 2006 (the “Original Agreement”), by and among: Aileron Therapeutics, Inc. (formerly Renegade Therapeutics, Inc.), a Delaware corporation, having a principal place of business at 840 Memorial Drive, 2nd Floor, Cambridge, MA 02142 (“Licensee”); President and Fellows of Harvard College, Holyoke Center, Suite 727, 1350 Massachusetts Ave., Cambridge, MA (“Harvard”); and Dana-Farber Cancer Institute, Inc., 44 Binney Street, Boston, MA (“DFCI”). Harvard and DFCI shall be referred to together as “Licensors”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • June 2nd, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations
THIS AGREEMENT is effective as of the day of , 2001 (the “Effective Date”), between CALIFORNIA INSTITUTE OF TECHNOLOGY, 1200 East California Boulevard, Pasadena, California 91125 (“Caltech”) and Materia, Inc., having a principal place of business at 2531 Nina Street, Pasadena, CA 91107 (“Licensee”).
AILERON THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 2nd, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations • Delaware
EMPLOYMENT AGREEMENT (the “Agreement”) dated as of March 1, 2008, between Aileron Therapeutics, Inc., a Delaware corporation (the “Company”) and Joseph A. Yanchik III (the “Executive”).
AILERON THERAPEUTICS, INC. Incentive Stock Option Agreement Granted Under 2006 Stock Incentive PlanIncentive Stock Option Agreement • June 2nd, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations
AILERON THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Granted Under 2006 Stock Incentive PlanStock Option Agreement • June 2nd, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations
AILERON THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANIncentive Stock Option Agreement • June 2nd, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations
